ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Yuji Hiramatsu
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hiramatsu, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hiramatsu, Y.
Related Collections
Right arrow Extracorporeal circulation
Right arrowRelated Article

Ann Thorac Surg 2005;80:257-258
© 2005 The Society of Thoracic Surgeons

Original article: Cardiovascular

Invited commentary

Yuji Hiramatsu, MD, PhD

Department of Cardiac Surgery, Institute of Clinical Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, 305-8575 Japan

(Email: yuji3@md.tsukuba.ac.jp).

The first 20% of the full text of this article appears below.


   Introduction
 
This article by Kondo and colleagues is an important addition to the literature on our continuing struggle to achieve "platelet anesthesia" during cardiopulmonary bypass (CPB). Undoubtedly, FK633, a synthetic platelet glycoprotein (GP) IIb/IIIa inhibitor is one of the most promising platelet anesthetics available, because the drug has a relatively short half-life [1]. The authors’ pre-CPB dose strategy is aimed at shutting down the first and biggest burst of platelet activation, which occurs during the initial contact with the artificial surface and the initial exposure to tissue factor. This concept is quite attractive, and they previously demonstrated the successful inhibition of {alpha}-granule release throughout in vitro CPB with such a single dose regimen. However, as the authors mention, the bolus regimen of FK633 before this in vivo . . . [Full Text of this Article]


Related Article

Platelet Preservation With a Glycoprotein IIb/IIIa Inhibitor in a Porcine Cardiopulmonary Bypass Model
Norihiro Kondo, Yasuyuki Suzuki, Fuminori Wakayama, Yoshiko Tamai, Kaiqiang Ji, Kozo Fukui, and Ikuo Fukuda
Ann. Thorac. Surg. 2005 80: 251-257. [Abstract] [Full Text] [PDF]





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2005 by The Society of Thoracic Surgeons.